LGALS3 and Hepatic fibrosis: Given its involvement in multiple pathological settings, galectin-3 has become a therapeutic target, and genetic or pharmacological inhibition of galectin-3 improved renal dysfunction in different pathological conditions [171] and was also protective in experimental models of liver fibrosis [168,172,173].